Together with the degradation of SP-D by metalloproteinase (MMP) 9, discussed above (77), these modifications could also account for the difference in levels of SP-A and SP-D detected in the lungs and serum of patients with COPD or asthma, as discussed later. The gene discussed is SFTPD; the disease is asthma.